ZymoGenetics clinical trials
Acquired by Bristol-Myers Squibb, Oct 12, 2010 · source ↗
The registry lists 10 studies whose lead sponsor is ZymoGenetics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 26, 2012.
Before and after it joined Bristol-Myers Squibb
- First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- 10
- First submitted after ZymoGenetics became part of Bristol-Myers Squibb
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 9
- Status unknown
- 1
Registry sponsor names on this page
- ZymoGenetics10 studies
Something wrong with this grouping? Tell us on the Bristol-Myers Squibb page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Bristol-Myers Squibb studies →
- Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric ParticipantsCompletedNCT00859547Phase 4
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical HemostasisCompletedNCT00491608Phase 3
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- Immunogenicity and Safety Study of rThrombin in Surgical HemostasisCompletedNCT00813904Phase 4
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus InfectionStatus unknownNCT01001754Phase 2
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT00565539Phase 1
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell CarcinomaCompletedNCT00389285Phase 1/2
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- Study of Recombinant Human Thrombin for Bleeding During SurgeryCompletedNCT00245336Phase 3
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney CancerCompletedNCT00095108Phase 1
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- Study of Recombinant Human Thrombin for Bleeding During Autologous Skin GraftingCompletedNCT00371215Phase 2
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb
- Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's LymphomaCompletedNCT00347971Phase 1
Sponsor listed in the registry: ZymoGenetics · First submitted before ZymoGenetics became part of Bristol-Myers Squibb